ArticleJournal of materials science. Materials in medicine2026
Fabrication of cercosporin-loaded polydopamine- cloaked mesoporous silica nanoparticles enhanced photothermal-photodynamic and anticancer activity in pancreatic cancer.
Article in Journal of materials science. Materials in medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
The lack of tumor targeting ability and the failure of single therapeutic approaches are two challenges in the treatment of pancreatic cancer. Mesoporous silica (MS) nanoparticles of two sizes (MS50 and MS100) were fabricated and functionalized with polydopamine (PD), cercosporin (CE), and arginine-glycine-aspartic acid peptide (RP) for the dual purposes of photodynamic therapy (PDT) and photothermal therapy (PTT) aimed at integrin αvβ3 in pancreatic cancer. MS@PD-RP-CE were examined using several approaches, exhibiting selective drug release, enhanced photothermal conversion efficiency, and reactive oxygen species (ROS) generation under laser irradiation. MS100@PD-RP-CE exhibited enhanced cellular uptake and cytotoxicity against pancreatic cancer (PANC-1) in vitro, while selectively targeting pancreatic cancer cells over normal cells, in comparison to MS50@PD-RP-CE. The mechanism of cell death was analyzed utilizing Calcein-AM/PI, and nuclear staining techniques. MS100@PD-RP-CE demonstrated considerable biocompatibility, as shown by the hemolytic assay. Thus, MS100@PD-RP-CE demonstrates significant promise for the prospective treatment of pancreatic cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.